Diabetes, prediabetes and cardiovascular risk

The increase in the incidence of diabetes and prediabetes, the association with cardiovascular disease and the accompanying high morbidity and mortality make glucose perturbations a serious public health issue. The poor prognosis among patients with type 2 diabetes and cardiovascular disease may relate to several factors. There seems to be a misconception among cardiologists that diabetes is a nonfrequent, almost unexciting disease and if it exists, it is labelled as ‘mild’ and/or ‘easy to treat.’ If screened with an oral glucose tolerance test approximately two-thirds of patients with coronary artery disease, stable and unstable, and earlier unknown glucometabolic perturbations indeed have impaired glucose tolerance or newly detected diabetes. Both conditions are related to an increase in cardiovascular mortality and morbidity. The European guidelines for diabetes, prediabetes and cardiovascular disease recommend that all patients with cardiovascular disease manifestations are screened with an oral glucose tolerance test. Many cardiologists seem more focused on the manifestation of the cardiac condition, not fully understanding the need for simultaneous and aggressive interactions directed towards the underlying metabolic disorder and the frequently existing concomitant risk factors. Treatment must be multifactorial and target driven. Treatment targets are stricter for patients with diabetes than those without diabetes. Patient management according to such standards is highly rewarding but necessitates transprofessional collaboration between cardiologists and diabetologists to be successfully accomplished. Eur J Cardiovasc Prev Rehabil 17 (Suppl 1):S9-S14 © 2010 The European Society of Cardiology

[1]  J. Shaw,et al.  Risk of Cardiovascular and All-Cause Mortality in Individuals With Diabetes Mellitus, Impaired Fasting Glucose, and Impaired Glucose Tolerance: The Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) , 2007, Circulation.

[2]  S. Yusuf,et al.  Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). , 2008, American heart journal.

[3]  A. Hungin,et al.  Impaired glucose tolerance: qualitative and quantitative study of general practitioners' knowledge and perceptions , 2002, BMJ : British Medical Journal.

[4]  A. Hamsten,et al.  Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study , 2002, The Lancet.

[5]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[6]  R. Klein,et al.  Onset of NIDDM occurs at Least 4–7 yr Before Clinical Diagnosis , 1992, Diabetes Care.

[7]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[8]  J. Tuomilehto,et al.  Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. , 2002, European heart journal.

[9]  L. Rydén,et al.  Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart , 2008, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[10]  S. Yusuf,et al.  The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. , 1999, Diabetes care.

[11]  H. Gerstein,et al.  Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). , 2008, American heart journal.

[12]  G. Rossi,et al.  Diagnosis and Classification of Diabetes Mellitus The information that follows is based largely on the reports of the Expert Committee on the Diagnosis and Classification of Diabetes (Diabetes Care 20:1183–1197, 1997, and Diabetes Care 26:3160–3167, 2003). , 2008, Diabetes Care.

[13]  H. Keen,et al.  HYPERGLYCÆMIA AND DIABETES MELLITUS , 1976, The Lancet.

[14]  Beverley Balkau,et al.  High Blood Glucose Concentration Is a Risk Factor for Mortality in Middle-Aged Nondiabetic Men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study , 1998, Diabetes Care.

[15]  L. V. Van Gaal,et al.  Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes. , 2007, European heart journal.

[16]  D. Hu,et al.  The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey. , 2006, European heart journal.

[17]  K. Yano,et al.  Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program. , 1999, Diabetes care.

[18]  U. Zeymer,et al.  Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: results of the randomised STOP-NIDDM trial electrocardiography substudy , 2004, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[19]  D. Mills,et al.  STARCH EMBOLI IN TRANSPLANTED KIDNEYS , 1974 .

[20]  J. A. Hunt,et al.  Variation of Postprandial Plasma Glucose, Palatability, and Symptoms Associated With a Standardized Mixed Test Meal Versus 75 g Oral Glucose , 1998, Diabetes Care.

[21]  L. Rydén,et al.  Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. , 2006, European heart journal.

[22]  E. Feskens,et al.  Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.

[23]  F. Ovalle 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes , 2009 .

[24]  M. Laakso,et al.  Understanding patient needs Diabetology for cardiologists , 2003 .

[25]  M. Harris,et al.  Diabetes and decline in heart disease mortality in US adults. , 1999, JAMA.

[26]  Maria Mori Brooks,et al.  A randomized trial of therapies for type 2 diabetes and coronary artery disease. , 2009, The New England journal of medicine.

[27]  Roberto Ferrari,et al.  The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. , 2004, European heart journal.

[28]  M. Shipley,et al.  CORONARY-HEART-DISEASE RISK AND IMPAIRED GLUCOSE TOLERANCE The Whitehall Study , 1980, The Lancet.

[29]  M. Laakso,et al.  Diabetology for cardiologists , 2003 .

[30]  Copeman Pw,et al.  THE AMERICAN AND HIS DIET. , 1964 .

[31]  L. Rydén,et al.  The impact of infarct type on the reliability of early oral glucose tolerance testing in patients with myocardial infarction. , 2010, International journal of cardiology.

[32]  L. Rydén,et al.  Oral Glucose Tolerance Test: A Reliable Tool for Early Detection of Glucose Abnormalities in Patients With Acute Myocardial Infarction in Clinical Practice , 2008, Diabetes Care.

[33]  L. Rydén,et al.  Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart , 2006, Heart.

[34]  V. Mohan Cardiovascular risk profile assessment in glucose‐intolerant Asian individuals—an evaluation of the World Health Organization two‐step strategy: the DECODA Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Asia) , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[35]  O. Pedersen,et al.  Effect of a multifactorial intervention on mortality in type 2 diabetes. , 2008, The New England journal of medicine.

[36]  Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. , 1999, Lancet.

[37]  Peter Lindgren,et al.  Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary , 2007 .

[38]  M. Hanefeld,et al.  Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. , 2004, European heart journal.

[39]  E. Feskens,et al.  Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. , 2001, Archives of internal medicine.

[40]  Markolf Hanefeld,et al.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.

[41]  M. Laakso,et al.  Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial , 2006, The Lancet.

[42]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[43]  A. Lindahl,et al.  Undiagnosed dysglycaemia and inflammation in cardiovascular disease , 2006, European journal of clinical investigation.

[44]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[45]  K. Malmberg,et al.  Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. , 2004, Journal of the American College of Cardiology.

[46]  S. Lamont,et al.  Screening for Type 2 diabetes: is it worthwhile? Views of general practitioners and practice nurses , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[47]  L. Rydén,et al.  Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. , 2007, European heart journal.